CN109464621A - 一种治疗湿疹皮炎的外用制剂及其制备方法 - Google Patents
一种治疗湿疹皮炎的外用制剂及其制备方法 Download PDFInfo
- Publication number
- CN109464621A CN109464621A CN201811408500.3A CN201811408500A CN109464621A CN 109464621 A CN109464621 A CN 109464621A CN 201811408500 A CN201811408500 A CN 201811408500A CN 109464621 A CN109464621 A CN 109464621A
- Authority
- CN
- China
- Prior art keywords
- external preparation
- rare earth
- preparation
- astaxanthin
- treating eczema
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 95
- 201000004624 Dermatitis Diseases 0.000 title claims abstract description 73
- 208000010668 atopic eczema Diseases 0.000 title claims abstract description 68
- 229910052761 rare earth metal Inorganic materials 0.000 claims abstract description 54
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 claims abstract description 37
- 239000001168 astaxanthin Substances 0.000 claims abstract description 37
- 229940022405 astaxanthin Drugs 0.000 claims abstract description 37
- 235000013793 astaxanthin Nutrition 0.000 claims abstract description 37
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 claims abstract description 37
- 229920000858 Cyclodextrin Polymers 0.000 claims abstract description 30
- 239000001116 FEMA 4028 Substances 0.000 claims abstract description 30
- 229960004853 betadex Drugs 0.000 claims abstract description 30
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims abstract description 27
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims abstract description 27
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 claims abstract description 20
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 claims abstract description 20
- 229960004949 glycyrrhizic acid Drugs 0.000 claims abstract description 20
- 239000001685 glycyrrhizic acid Substances 0.000 claims abstract description 20
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 claims abstract description 20
- 235000019410 glycyrrhizin Nutrition 0.000 claims abstract description 20
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims abstract description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 49
- 239000008213 purified water Substances 0.000 claims description 40
- 239000002562 thickening agent Substances 0.000 claims description 24
- 238000005303 weighing Methods 0.000 claims description 23
- 150000002148 esters Chemical class 0.000 claims description 18
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims description 17
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims description 17
- 229940041616 menthol Drugs 0.000 claims description 17
- 239000000284 extract Substances 0.000 claims description 16
- -1 ethoxycarbonylmethyl Chemical group 0.000 claims description 15
- 150000002910 rare earth metals Chemical class 0.000 claims description 15
- 239000002994 raw material Substances 0.000 claims description 15
- 238000003756 stirring Methods 0.000 claims description 14
- 238000004090 dissolution Methods 0.000 claims description 12
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 10
- 229910052779 Neodymium Inorganic materials 0.000 claims description 9
- 239000003507 refrigerant Substances 0.000 claims description 9
- XHXUANMFYXWVNG-ADEWGFFLSA-N (-)-Menthyl acetate Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1OC(C)=O XHXUANMFYXWVNG-ADEWGFFLSA-N 0.000 claims description 8
- 229910052684 Cerium Inorganic materials 0.000 claims description 8
- VUNOFAIHSALQQH-UHFFFAOYSA-N Ethyl menthane carboxamide Chemical compound CCNC(=O)C1CC(C)CCC1C(C)C VUNOFAIHSALQQH-UHFFFAOYSA-N 0.000 claims description 8
- 229910052772 Samarium Inorganic materials 0.000 claims description 8
- 229910052746 lanthanum Inorganic materials 0.000 claims description 8
- 235000007516 Chrysanthemum Nutrition 0.000 claims description 7
- 244000189548 Chrysanthemum x morifolium Species 0.000 claims description 7
- 229910052693 Europium Inorganic materials 0.000 claims description 7
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 7
- ZHNUHDYFZUAESO-UHFFFAOYSA-N formamide Substances NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 claims description 6
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 5
- 229920002101 Chitin Polymers 0.000 claims description 5
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 5
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 5
- 229910052777 Praseodymium Inorganic materials 0.000 claims description 5
- HDSBZMRLPLPFLQ-UHFFFAOYSA-N Propylene glycol alginate Chemical compound OC1C(O)C(OC)OC(C(O)=O)C1OC1C(O)C(O)C(C)C(C(=O)OCC(C)O)O1 HDSBZMRLPLPFLQ-UHFFFAOYSA-N 0.000 claims description 5
- 229920002125 Sokalan® Polymers 0.000 claims description 5
- UJNOLBSYLSYIBM-WISYIIOYSA-N [(1r,2s,5r)-5-methyl-2-propan-2-ylcyclohexyl] (2r)-2-hydroxypropanoate Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1OC(=O)[C@@H](C)O UJNOLBSYLSYIBM-WISYIIOYSA-N 0.000 claims description 5
- 229960001631 carbomer Drugs 0.000 claims description 5
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 5
- 235000010409 propane-1,2-diol alginate Nutrition 0.000 claims description 5
- 239000000770 propane-1,2-diol alginate Substances 0.000 claims description 5
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims description 4
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 claims description 4
- 239000001605 (5-methyl-2-propan-2-ylcyclohexyl) acetate Substances 0.000 claims description 4
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 claims description 4
- XHXUANMFYXWVNG-UHFFFAOYSA-N D-menthyl acetate Natural products CC(C)C1CCC(C)CC1OC(C)=O XHXUANMFYXWVNG-UHFFFAOYSA-N 0.000 claims description 4
- 229910052692 Dysprosium Inorganic materials 0.000 claims description 4
- 229910052691 Erbium Inorganic materials 0.000 claims description 4
- WEEGYLXZBRQIMU-UHFFFAOYSA-N Eucalyptol Chemical compound C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 claims description 4
- 229910052688 Gadolinium Inorganic materials 0.000 claims description 4
- 229910052689 Holmium Inorganic materials 0.000 claims description 4
- 229910052765 Lutetium Inorganic materials 0.000 claims description 4
- 229920002472 Starch Polymers 0.000 claims description 4
- 229910052771 Terbium Inorganic materials 0.000 claims description 4
- 229910052775 Thulium Inorganic materials 0.000 claims description 4
- 229910052769 Ytterbium Inorganic materials 0.000 claims description 4
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 4
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 claims description 4
- YZXZAUAIVAZWFN-UHFFFAOYSA-N bis(5-methyl-2-propan-2-ylcyclohexyl) butanedioate Chemical compound CC(C)C1CCC(C)CC1OC(=O)CCC(=O)OC1C(C(C)C)CCC(C)C1 YZXZAUAIVAZWFN-UHFFFAOYSA-N 0.000 claims description 4
- 229940116229 borneol Drugs 0.000 claims description 4
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 claims description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 4
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 claims description 4
- 239000001341 hydroxy propyl starch Substances 0.000 claims description 4
- 235000013828 hydroxypropyl starch Nutrition 0.000 claims description 4
- 239000001525 mentha piperita l. herb oil Substances 0.000 claims description 4
- 150000002729 menthone derivatives Chemical class 0.000 claims description 4
- 235000019477 peppermint oil Nutrition 0.000 claims description 4
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 4
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 4
- 239000008107 starch Substances 0.000 claims description 4
- 235000019698 starch Nutrition 0.000 claims description 4
- 229910052727 yttrium Inorganic materials 0.000 claims description 4
- 229920001353 Dextrin Polymers 0.000 claims description 3
- 239000004375 Dextrin Substances 0.000 claims description 3
- RWAXQWRDVUOOGG-UHFFFAOYSA-N N,2,3-Trimethyl-2-(1-methylethyl)butanamide Chemical compound CNC(=O)C(C)(C(C)C)C(C)C RWAXQWRDVUOOGG-UHFFFAOYSA-N 0.000 claims description 3
- 240000004584 Tamarindus indica Species 0.000 claims description 3
- 235000004298 Tamarindus indica Nutrition 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 3
- 235000019425 dextrin Nutrition 0.000 claims description 3
- 239000010642 eucalyptus oil Substances 0.000 claims description 3
- 229940044949 eucalyptus oil Drugs 0.000 claims description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 3
- 229910052706 scandium Inorganic materials 0.000 claims description 3
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims description 3
- SJZRECIVHVDYJC-UHFFFAOYSA-N 4-hydroxybutyric acid Chemical compound OCCCC(O)=O SJZRECIVHVDYJC-UHFFFAOYSA-N 0.000 claims 1
- 239000001913 cellulose Substances 0.000 claims 1
- 229920002678 cellulose Polymers 0.000 claims 1
- 235000010980 cellulose Nutrition 0.000 claims 1
- 230000001139 anti-pruritic effect Effects 0.000 abstract description 15
- 230000000694 effects Effects 0.000 abstract description 12
- 239000003908 antipruritic agent Substances 0.000 abstract description 11
- 230000001225 therapeutic effect Effects 0.000 abstract description 10
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 9
- 206010012434 Dermatitis allergic Diseases 0.000 abstract description 8
- 201000008937 atopic dermatitis Diseases 0.000 abstract description 8
- 238000000034 method Methods 0.000 abstract description 8
- 230000003266 anti-allergic effect Effects 0.000 abstract description 7
- 206010012442 Dermatitis contact Diseases 0.000 abstract description 6
- 201000004681 Psoriasis Diseases 0.000 abstract description 6
- 208000010247 contact dermatitis Diseases 0.000 abstract description 6
- 230000001954 sterilising effect Effects 0.000 abstract description 5
- 238000004659 sterilization and disinfection Methods 0.000 abstract description 5
- 230000003449 preventive effect Effects 0.000 abstract description 4
- 230000008901 benefit Effects 0.000 abstract description 3
- 230000003013 cytotoxicity Effects 0.000 abstract description 3
- 231100000135 cytotoxicity Toxicity 0.000 abstract description 3
- 238000010306 acid treatment Methods 0.000 abstract description 2
- 239000002552 dosage form Substances 0.000 abstract description 2
- 239000004615 ingredient Substances 0.000 abstract description 2
- 230000003078 antioxidant effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 description 22
- 239000007921 spray Substances 0.000 description 18
- 239000003349 gelling agent Substances 0.000 description 13
- 229950005162 benexate Drugs 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 229940079593 drug Drugs 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 6
- 206010015150 Erythema Diseases 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 208000003251 Pruritus Diseases 0.000 description 5
- 230000002757 inflammatory effect Effects 0.000 description 5
- 244000157790 Buglossoides arvense Species 0.000 description 4
- 235000004256 Buglossoides arvense Nutrition 0.000 description 4
- 244000025254 Cannabis sativa Species 0.000 description 4
- 241001251949 Xanthium sibiricum Species 0.000 description 4
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 4
- 239000004327 boric acid Substances 0.000 description 4
- PNZXMIKHJXIPEK-UHFFFAOYSA-N cyclohexanecarboxamide Chemical compound NC(=O)C1CCCCC1 PNZXMIKHJXIPEK-UHFFFAOYSA-N 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 210000003712 lysosome Anatomy 0.000 description 4
- 230000001868 lysosomic effect Effects 0.000 description 4
- 238000002604 ultrasonography Methods 0.000 description 4
- WHBMMWSBFZVSSR-UHFFFAOYSA-M 3-hydroxybutyrate Chemical compound CC(O)CC([O-])=O WHBMMWSBFZVSSR-UHFFFAOYSA-M 0.000 description 3
- 241000205585 Aquilegia canadensis Species 0.000 description 3
- 241000605422 Asparagus asparagoides Species 0.000 description 3
- 244000247747 Coptis groenlandica Species 0.000 description 3
- 235000002991 Coptis groenlandica Nutrition 0.000 description 3
- 241000270273 Ptyas dhumnades Species 0.000 description 3
- WHBMMWSBFZVSSR-UHFFFAOYSA-N R3HBA Natural products CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 description 3
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 3
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 3
- 244000261559 Smilax china Species 0.000 description 3
- 235000000485 Smilax china Nutrition 0.000 description 3
- 240000009022 Smilax rotundifolia Species 0.000 description 3
- 235000003205 Smilax rotundifolia Nutrition 0.000 description 3
- 244000046101 Sophora japonica Species 0.000 description 3
- 235000010586 Sophora japonica Nutrition 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000003292 glue Substances 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 210000004400 mucous membrane Anatomy 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 229910052710 silicon Inorganic materials 0.000 description 3
- 239000010703 silicon Substances 0.000 description 3
- 229940032147 starch Drugs 0.000 description 3
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 2
- 241001233914 Chelidonium majus Species 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 206010012435 Dermatitis and eczema Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 241001506371 Kadsura Species 0.000 description 2
- 240000007849 Macleaya cordata Species 0.000 description 2
- 244000246386 Mentha pulegium Species 0.000 description 2
- 235000016257 Mentha pulegium Nutrition 0.000 description 2
- 235000004357 Mentha x piperita Nutrition 0.000 description 2
- 240000004980 Rheum officinale Species 0.000 description 2
- 235000008081 Rheum officinale Nutrition 0.000 description 2
- 240000003152 Rhus chinensis Species 0.000 description 2
- 235000014220 Rhus chinensis Nutrition 0.000 description 2
- 241000501113 Sargentodoxa cuneata Species 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 239000005864 Sulphur Substances 0.000 description 2
- 230000033540 T cell apoptotic process Effects 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 241001078983 Tetradium ruticarpum Species 0.000 description 2
- 230000002924 anti-infective effect Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000004154 complement system Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000009969 fructus bruceae Substances 0.000 description 2
- 239000003862 glucocorticoid Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 235000001050 hortel pimenta Nutrition 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 150000003904 phospholipids Chemical group 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000011787 zinc oxide Substances 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 241000143060 Americamysis bahia Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241001645380 Bassia scoparia Species 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 201000007336 Cryptococcosis Diseases 0.000 description 1
- 241000221204 Cryptococcus neoformans Species 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 244000234609 Portulaca oleracea Species 0.000 description 1
- 235000001855 Portulaca oleracea Nutrition 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 240000000203 Salix gracilistyla Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 1
- 240000001949 Taraxacum officinale Species 0.000 description 1
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 description 1
- 206010043189 Telangiectasia Diseases 0.000 description 1
- ISWQCIVKKSOKNN-UHFFFAOYSA-L Tiron Chemical compound [Na+].[Na+].OC1=CC(S([O-])(=O)=O)=CC(S([O-])(=O)=O)=C1O ISWQCIVKKSOKNN-UHFFFAOYSA-L 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- ILKJAFIWWBXGDU-MOGDOJJUSA-N amcinonide Chemical compound O([C@@]1([C@H](O2)C[C@@H]3[C@@]1(C[C@H](O)[C@]1(F)[C@@]4(C)C=CC(=O)C=C4CC[C@H]13)C)C(=O)COC(=O)C)C12CCCC1 ILKJAFIWWBXGDU-MOGDOJJUSA-N 0.000 description 1
- 229960003099 amcinonide Drugs 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229910052789 astatine Inorganic materials 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 235000013532 brandy Nutrition 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960002344 dexamethasone sodium phosphate Drugs 0.000 description 1
- PLCQGRYPOISRTQ-FCJDYXGNSA-L dexamethasone sodium phosphate Chemical compound [Na+].[Na+].C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COP([O-])([O-])=O)(O)[C@@]1(C)C[C@@H]2O PLCQGRYPOISRTQ-FCJDYXGNSA-L 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000001408 fungistatic effect Effects 0.000 description 1
- 229910021389 graphene Inorganic materials 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940088592 immunologic factor Drugs 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- QEFYFXOXNSNQGX-UHFFFAOYSA-N neodymium atom Chemical compound [Nd] QEFYFXOXNSNQGX-UHFFFAOYSA-N 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 208000001297 phlebitis Diseases 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 108090000765 processed proteins & peptides Chemical group 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 238000007348 radical reaction Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 150000003317 samarium compounds Chemical class 0.000 description 1
- 238000006748 scratching Methods 0.000 description 1
- 230000002393 scratching effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 208000009056 telangiectasis Diseases 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/58—Reptiles
- A61K35/583—Snakes; Lizards, e.g. chameleons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/282—Artemisia, e.g. wormwood or sagebrush
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/287—Chrysanthemum, e.g. daisy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/30—Boraginaceae (Borage family), e.g. comfrey, lungwort or forget-me-not
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/483—Gleditsia (locust)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/489—Sophora, e.g. necklacepod or mamani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/534—Mentha (mint)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/708—Rheum (rhubarb)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/90—Smilacaceae (Catbrier family), e.g. greenbrier or sarsaparilla
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Dispersion Chemistry (AREA)
- Emergency Medicine (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明涉及制剂技术领域,具体涉及一种治疗湿疹皮炎的外用制剂及其制备方法,它采用稀土元素、甘草酸、虾青素、β‑环糊精、清凉剂为主要成分。本发明各成分起到协同效果,不仅有效发挥稀土元素、甘草酸治疗皮炎的效果,稳定发挥虾青素的抗氧化效果,还有透皮效率高,剂型稳定等优势。本发明的外用制剂兼有抗过敏、抗瘙痒、抗红肿等多种防治作用,止痒效果明显,可用于湿疹、过敏性皮炎、接触性皮炎、银屑病等皮炎的消炎、止痒、杀菌等治疗作用。本发明的制备方法步骤简单,无体外细胞毒性,安全有效,质量可控。
Description
技术领域
本发明涉及制剂技术领域,具体涉及一种治疗湿疹皮炎的外用制剂及其制备方法。
背景技术
湿疹皮炎是常见的皮肤病,严重的影响了患者的生活和工作,湿疹的发病原因非常复杂,简单的分为内在因素和外在因素,二者之间难分主次,通常是互相联系,协同作用。外因如化学制剂、化妆品、动物毒素、鱼虾、花粉、尘埃、日晒、搔抓等。内因包括遗传因素、精神因素、机体的免疫因素、代谢因素等。心理因素对皮炎湿疹类皮肤病的影响越来越受到重视,皮炎湿疹的发生还可能与饮食、生活规律、环境等有一定关系。现有的关于治疗皮炎的药物如下:申请号为200810040794.9的中国发明专利公开了一种用于制备抗湿疹皮炎产品的配方及其制备方法,该抗湿疹皮炎产品是抗过敏组分0.01%~20.0%,抗瘙痒组分0.1%~20.0%,抗感染组分0.1%~20.0%,果绿适量,溶剂加至1000ml;其中,所述的抗过敏组分是弱效糖皮质激素,所述的弱效糖皮质激素是地塞米松或氢化可的松中的一种或多种;所述的抗瘙痒组分是薄荷脑或地塞米松磷酸钠中的一种或多种;所述的抗感染组分是苯酚和硼酸。
专利CN201220281655.7公开了一种治疗人面部螨性皮炎的药物及其制备方法,其特别适用于 治疗酒渣鼻和青春痘。其特征在于它由下述方法制备,向带有加热和搅拌的容器中投入药用硅霜并进行加热和搅拌,加热温度为39-45℃,搅拌速度为50-70 转/分钟,然后按顺序依次将薄荷脑、氧化锌、硼酸、升华硫磺、水杨酸、鸭胆子油、月桂氮酮、明矾甘油溶液投入装有药用硅霜的容器中进行混合搅拌,搅 拌均匀后将其送入研磨机内进行研磨,研磨后将其送入乳化罐乳化成细腻软膏, 其药用硅霜、薄荷脑、氧化锌、硼酸、升华硫磺、水杨酸、鸭胆子油、月桂氮 酮、明矾甘油溶液的重量比是68-78∶1.5-2.7∶6.5-7.6∶1.5-2.7∶6.5-7.6∶ 0.5-1.8∶0.5-1.5∶0.5-1.5∶3.5-5.2。
但是,以上技术存在如下不足:1、长期使用激素类药会产生激素依赖症,导致皮肤粘膜的毛细血管扩张而引起全身的毒副作用;易造成细菌和真菌感染;
2、传统治疗湿疹的外用药物还常选择单纯中草药类外用药物,此法通常见效慢,易反弹。
发明内容
为了克服现有技术中存在的缺点和不足,本发明的目的在于提供一种治疗湿疹皮炎的外用制剂,该外用制剂兼有抗过敏、抗瘙痒、抗红肿等多种防治作用,止痒效果明显,可用于湿疹、过敏性皮炎、接触性皮炎、银屑病等皮炎的消炎、止痒、杀菌等治疗作用。
本发明的目的在于提供一种治疗湿疹皮炎的外用制剂的制备方法,该制备方法步骤简单简单,无体外细胞毒性,安全有效,质量可控。
本发明的目的通过下述技术方案实现:一种治疗湿疹皮炎的外用制剂,其特征在于:它采用稀土元素、甘草酸、虾青素、β-环糊精、清凉剂为主要成分,具体的,该外用制剂由如下重量百分比的原料组成:稀土元素0.01%-5%,甘草酸0.1%-5%,虾青素0.001-1.0%,β-环糊精0.05%-5%,清凉剂0.001%-1.0%,增稠剂0.1%-10%,余量为纯化水。
一种治疗湿疹皮炎的外用制剂的制备方法,其特征在于:包括如下步骤:
步骤1:称取虾青素、β-环糊精,加入占纯化水总重量30%-70%的纯化水,以20000Hz~40000Hz的超声频率进行超声分散,于45-150°C温度下搅拌溶解,得到溶液一,即虾青素-β-环糊精包合物溶液;
步骤2:称取清凉剂,倒入剩余的纯化水,加热至60-80℃溶解,冷却至室温后,加入稀土元素,得到溶液二;
步骤3:将步骤1与步骤2得到的溶液混合搅拌,一种治疗湿疹皮炎的外用制剂。
当该外用制剂制成凝胶时,步骤二中加入增稠剂;当该外用制剂制成喷剂时,无需加入增稠剂。
优选的,所述稀土元素为La、Ce、Pr、Nd、Pm、Sm、Eu、Gd、Tb、Dy、Ho、Er、Tm、Yb、Lu、Y和Sc中的至少一种。
更为优选的,所述稀土元素是由La和Ce以重量比1-3:1组成的混合物;或者,所述稀土元素是由Nd和Sm以重量比0.5-1.5:1组成的混合物;或者,所述稀土元素是由Pr、Pm和Eu以重量比0.8-1.2:1.4-2.2:1组成的混合物。
关于稀土元素作为抗炎、杀菌药物使用已有很多报道。60年代,人们发现钛铁试剂稀土或磺基水杨酸稀土是潜在的抗炎、杀菌药物。使用钛铁试剂、钕、钐化合物治疗湿疹皮肤炎、过敏性皮肤炎、龈炎、静脉炎等,其疗效不次于肾上腺皮质激素药物。此外,稀土较易形成三元配合物,易溶于水,对枯草芽孢杆菌、金黄色葡萄球菌、绿脓杆菌等的抑菌有很好的抑制效果,其对白色念珠菌和新型隐球菌的抑菌效果甚至鼻氯霉素、青霉素作用还好。稀土元素的治疗性药理作用是由于稀土离子与细胞磷脂和肽链上的羧基有较强的亲和力,因此能稳定在细胞膜及溶酶体上,从而抑制溶酶体释放炎症物质;稀土元素不含抗菌素和激素,用于治疗接触性、过敏性皮炎,大部分为局部外用药,长期使用无副作用。
甘草酸是甘草的有效成分,其选择性诱导成熟的T淋巴细胞凋亡,调节淋巴细胞数量和功能,纠正外周血T淋巴细胞亚群的紊乱,具有抗炎、抗变态反应的药理作用;其机制为抑制抗体(IgG、IgE)生成,多靶点地抑制补体系统,抑制炎性细胞因子和炎症介质生成,以及对抗炎症介质的致炎作用。
虾青素是一种广泛存在于动物界的类胡萝卜素。在虾青素分子中,包含很长的共轭双键,其末端有不饱和酮和羟基,又构成α-羟基酮,这些结构具有活泼的电子效应,能与自由基反应起到清除自由基的作用,从而达到抗氧化的目的。虾青素能够刺激淋巴细胞的扩增,提高人体免疫球蛋白的产量,增强天然杀死细胞毒素的活性,有效减轻DNA损伤,通过多种方式支持人体的免疫功能。利用超声技术可将虾青素分子进入β-环糊精的空腔中,利于虾青素—β环糊精包合物的形成,提高了虾青素的稳定性与抗氧化性,
清凉剂作用于皮肤或者粘膜上时,有清凉止痒作用,可以有效缓解因皮炎引起的瘙痒、红肿等症状。
优选的,所述清凉剂为薄荷酯、薄荷酰胺、薄荷醇、薄荷酮、薄荷油、薄荷脑、桉叶油、菊花精、清凉醇和冰片中的至少一种。所述薄荷酯为3-羟基丁酸薄荷酯、琥珀酸薄荷酯、乳酸薄荷酯、戊二酸薄荷酯和乙酸薄荷酯中的至少一种;所述薄荷酰胺为N-(乙氧羰基甲基)-对薄荷烷-3-甲酰胺、N-乙基-对薄荷基-3-甲酰胺、N-(4-氰基甲基苯基)对-薄荷酰胺、2-异丙基-5-甲基-N-(2-(吡啶-4-基)乙基)环己烷甲酰胺和2-异丙基-N,2,3-三甲基丁酰胺中的至少一种。
更为优选的,所述清凉剂是由菊花精、薄荷脑和清凉醇以重量比2-4:1-2:1组成的混合物;或者,所述清凉剂是由薄荷醇、乳酸薄荷酯、2-异丙基-5-甲基-N-(2-(吡啶-4-基)乙基)环己烷甲酰胺以重量比1-2:0.5-1.5:1组成的混合物。清凉剂作用于皮肤或者粘膜上时,有清凉止痒作用,可以有效缓解因皮炎引起的瘙痒、红肿等症状。
优选的,所述增稠剂为甲基纤维素、羟乙基纤维素、羟丙基甲基纤维素、羧甲基纤维素钠、海藻酸丙二醇酯、卡波姆、淀粉磷酸酯钠、甲壳素、罗望子胶和羟丙基淀粉醚中的至少一种。更为优选的,所述增稠剂是由羧甲基纤维素钠、卡波姆和甲壳素以重量比1.5-2.5:0.5-1.5:1组成的混合物;或者,所述增稠剂是由羟乙基纤维素、海藻酸丙二醇酯和羟丙基淀粉醚以重量比0.4-0.8:0.8-1.2:1组成的混合物。
该治疗湿疹皮炎的外用制剂还包括中药提取物1%-5%,所述中药提取物包括如下重量份的原料:土茯苓10-20份、大黄5-15份、槐胶5-15份、菝葜1-3份、乌梢蛇4-8份、黄芩1-3份、金银花1-3份、苦参3-5份,皂刺1-3份、赤芍8-12份,艾叶4-8份、苍耳1-3份、甘草3-7份和紫草1-5份。本发明的中药提取物通过采用上述中药配伍,配方合理,各药味相辅相成,对湿疹、过敏性皮炎、接触性皮炎、银屑病等皮炎具有消炎、止痒、杀菌等治疗作用,还可以防止复发。
本发明的有益效果在于:本发明的外用制剂采用稀土元素、甘草酸、虾青素、β-环糊精、清凉剂为主要成分,稀土元素中的三价稀土离子与细胞磷脂有较强的亲和力,它能稳定在溶酶体上,通过稳定细胞膜及溶酶体膜,抑制酶体的分泌,从而达到抗炎的目的。甘草酸选择性诱导成熟的T淋巴细胞凋亡,调节淋巴细胞数量和功能,纠正外周血T淋巴细胞亚群的紊乱;甘草酸抑制抗体生成,多靶点地抑制补体系统,抑制炎性细胞因子和炎症介质生成。用β-环糊精包合虾青素再加入到配方中,可解决虾青素易氧化而失去活性的问题,同时β-环糊精还能包结皮肤中渗出的多不饱和脂肪酸,防止其氧化变质,抑制自由基形成,减少皮肤感染和炎症,清凉剂具有清新的凉气,能缓解皮炎而引起的红肿、瘙痒症状。本发明各成分起到协同效果,不仅有效发挥稀土元素、甘草酸治疗皮炎的效果,稳定发挥虾青素的抗氧化效果,还有透皮效率高,剂型稳定等优势。本发明的外用制剂兼有抗过敏、抗瘙痒、抗红肿等多种防治作用,止痒效果明显,可用于湿疹、过敏性皮炎、接触性皮炎、银屑病等皮炎的消炎、止痒、杀菌等治疗作用。本发明的制备方法步骤简单,无体外细胞毒性,安全有效,质量可控。
具体实施方式
为了便于本领域技术人员的理解,下面结合实施例对本发明作进一步的说明,实施方式提及的内容并非对本发明的限定。
实施例1
一种治疗湿疹皮炎的外用制剂,所述外用制剂为喷雾剂,喷雾剂包括如下重量百分比的原料:稀土元素0.01%、甘草酸0.1%,虾青素0.001%,β-环糊精0.05%、清凉剂0.001%,纯化水余量;
一种治疗湿疹皮炎的外用制剂的制备方法,其特征在于:包括如下步骤:
步骤1:称取虾青素、β-环糊精,加入占纯化水总重量30%的纯化水,以40000Hz的超声频率进行超声分散,于45°C温度下搅拌溶解,得到溶液一,即虾青素-β-环糊精包合物溶液;
步骤2:称取清凉剂,倒入剩余的纯化水,加热至60℃溶解,冷却至室温后,加入稀土元素,得到溶液二;
步骤3:将步骤1与步骤2得到的溶液混合搅拌,一种治疗湿疹皮炎的外用制剂。
所述稀土元素为La、Ce、Pr、Nd、Pm、Sm或Eu。
所述清凉剂为薄荷酯。所述薄荷酯为3-羟基丁酸薄荷酯、琥珀酸薄荷酯、乳酸薄荷酯、戊二酸薄荷酯或乙酸薄荷酯。
实施例2
一种治疗湿疹皮炎的外用制剂,所述外用制剂为喷雾剂,喷雾剂包括如下重量百分比的原料:稀土元素0.1%、甘草酸2%、虾青素0.05%、β-环糊精2%、清凉剂0.01%,纯化水余量;
一种治疗湿疹皮炎的外用制剂的制备方法,其特征在于:包括如下步骤:
步骤1:称取虾青素、β-环糊精,加入占纯化水总重量50%的纯化水,以30000Hz的超声频率进行超声分散,于100°C温度下搅拌溶解,得到溶液一,即虾青素-β-环糊精包合物溶液;
步骤2:称取清凉剂,倒入剩余的纯化水,加热至70℃溶解,冷却至室温后,加入稀土元素,得到溶液二;
步骤3:将步骤1与步骤2得到的溶液混合搅拌,一种治疗湿疹皮炎的外用制剂。
所述稀土元素为Gd、Tb、Dy、Ho、Er、Tm、Yb、Lu、Y或Sc。
所述清凉剂为薄荷酰胺。所述薄荷酰胺为N-(乙氧羰基甲基)-对薄荷烷-3-甲酰胺、N-乙基-对薄荷基-3-甲酰胺、N-(4-氰基甲基苯基)对-薄荷酰胺、2-异丙基-5-甲基-N-(2-(吡啶-4-基)乙基)环己烷甲酰胺或2-异丙基-N,2,3-三甲基丁酰胺。
实施例3
一种治疗湿疹皮炎的外用制剂,所述外用制剂为喷雾剂,喷雾剂包括如下重量百分比的原料:稀土元素0.5%、甘草酸5%,虾青素1.0%,β-环糊精5%、清凉剂0.5%,纯化水余量;
一种治疗湿疹皮炎的外用制剂的制备方法,其特征在于:包括如下步骤:
步骤1:称取虾青素、β-环糊精,加入占纯化水总重量70%的纯化水,以20000Hz的超声频率进行超声分散,于150°C温度下搅拌溶解,得到溶液一,即虾青素-β-环糊精包合物溶液;
步骤2:称取清凉剂,倒入剩余的纯化水,加热至80℃溶解,冷却至室温后,加入稀土元素,得到溶液二;
步骤3:将步骤1与步骤2得到的溶液混合搅拌,一种治疗湿疹皮炎的外用制剂。
所述稀土元素是由La和Ce以重量比1-3:1组成的混合物。
所述清凉剂为薄荷醇、薄荷酮、薄荷油、薄荷脑、桉叶油、菊花精、清凉醇或冰片。
实施例4
一种治疗湿疹皮炎的外用制剂,所述外用制剂为喷雾剂,喷雾剂包括如下重量百分比的原料:稀土元素0.8%、甘草酸2%、虾青素1.0%、β-环糊精3%、清凉剂0.8%,纯化水余量;
一种治疗湿疹皮炎的外用制剂的制备方法,其特征在于:包括如下步骤:
步骤1:称取虾青素、β-环糊精,加入占纯化水总重量65%的纯化水,以30000Hz的超声频率进行超声分散,于120°C温度下搅拌溶解,得到溶液一,即虾青素-β-环糊精包合物溶液;
步骤2:称取清凉剂,倒入剩余的纯化水,加热至70℃溶解,冷却至室温后,加入稀土元素,得到溶液二;
步骤3:将步骤1与步骤2得到的溶液混合搅拌,一种治疗湿疹皮炎的外用制剂。
所述稀土元素是由Nd和Sm以重量比1:1组成的混合物。
所述清凉剂是由菊花精、薄荷脑和清凉醇以重量比3:1.5:1组成的混合物。
实施例5
一种治疗湿疹皮炎的外用制剂,所述外用制剂为喷雾剂,喷雾剂包括如下重量百分比的原料:稀土元素1%、甘草酸4%、虾青素0.8%、β-环糊精1%、清凉剂1.0%,纯化水余量;
一种治疗湿疹皮炎的外用制剂的制备方法,其特征在于:包括如下步骤:
步骤1:称取虾青素、β-环糊精,加入占纯化水总重量48%的纯化水,以30000Hz的超声频率进行超声分散,于100°C温度下搅拌溶解,得到溶液一,即虾青素-β-环糊精包合物溶液;
步骤2:称取清凉剂,倒入剩余的纯化水,加热至75℃溶解,冷却至室温后,加入稀土元素,得到溶液二;
步骤3:将步骤1与步骤2得到的溶液混合搅拌,一种治疗湿疹皮炎的外用制剂。
所述稀土元素是由Pr、Pm和Eu以重量比1:1.8:1组成的混合物。
所述清凉剂是由薄荷醇、乳酸薄荷酯、2-异丙基-5-甲基-N-(2-(吡啶-4-基)乙基)环己烷甲酰胺以重量比1.5:1:1组成的混合物。
实施例6
一种治疗湿疹皮炎的外用制剂,所述外用制剂为凝胶剂,凝胶剂包括如下重量百分比的原料:稀土元素0.01%、增稠剂0.1%、甘草酸0.1%%、虾青素0.009%、β-环糊精0.09%、清凉剂0.001%,纯化水余量。
一种治疗湿疹皮炎的外用制剂的制备方法,其特征在于:包括如下步骤:
步骤1:称取虾青素、β-环糊精,加入占纯化水总重量70%的纯化水,以40000Hz的超声频率进行超声分散,于50°C温度下搅拌溶解,得到溶液一,即虾青素-β-环糊精包合物溶液;
步骤2:称取清凉剂,倒入剩余的纯化水,加热至80℃溶解,冷却至室温后,加入稀土元素、增稠剂,得到溶液二;
步骤3:将步骤1与步骤2得到的溶液混合搅拌,一种治疗湿疹皮炎的外用制剂。
所述稀土元素为La、Ce、Pr、Nd、Pm、Sm或Eu。
所述清凉剂为薄荷酯。所述薄荷酯为3-羟基丁酸薄荷酯、琥珀酸薄荷酯、乳酸薄荷酯、戊二酸薄荷酯或乙酸薄荷酯。
所述增稠剂为甲基纤维素、羟乙基纤维素、羟丙基甲基纤维素或羧甲基纤维素钠。
实施例7
一种治疗湿疹皮炎的外用制剂,所述外用制剂为凝胶剂,凝胶剂包括如下重量百分比的原料:稀土元素0.1%、增稠剂1%、甘草酸2%、虾青素0.07%、β-环糊精2%、清凉剂0.01%,纯化水余量。
一种治疗湿疹皮炎的外用制剂的制备方法,其特征在于:包括如下步骤:
步骤1:称取虾青素、β-环糊精,加入占纯化水总重量60%的的纯化水,以30000Hz的超声频率进行超声分散,于90°C温度下搅拌溶解,得到溶液一,即虾青素-β-环糊精包合物溶液;
步骤2:称取清凉剂,倒入剩余的纯化水,加热至80℃溶解,冷却至室温后,加入稀土元素、增稠剂,得到溶液二;
步骤3:将步骤1与步骤2得到的溶液混合搅拌,一种治疗湿疹皮炎的外用制剂。
所述稀土元素为Gd、Tb、Dy、Ho、Er、Tm、Yb、Lu、Y或Sc。
所述清凉剂为薄荷酰胺。所述薄荷酰胺为N-(乙氧羰基甲基)-对薄荷烷-3-甲酰胺、N-乙基-对薄荷基-3-甲酰胺、N-(4-氰基甲基苯基)对-薄荷酰胺、2-异丙基-5-甲基-N-(2-(吡啶-4-基)乙基)环己烷甲酰胺和2-异丙基-N,2,3-三甲基丁酰胺中的至少一种。
所述增稠剂为海藻酸丙二醇酯、卡波姆或淀粉磷酸酯钠。
实施例8
一种治疗湿疹皮炎的外用制剂,所述外用制剂为凝胶剂,凝胶剂包括如下重量百分比的原料:稀土元素1.5%、增稠剂5%、甘草酸5%、虾青素1.0%、β-环糊精4%、清凉剂0.5%,纯化水余量。
一种治疗湿疹皮炎的外用制剂的制备方法,其特征在于:包括如下步骤:
步骤1:称取虾青素、β-环糊精,加入占纯化水总重量60%的的纯化水,以30000Hz的超声频率进行超声分散,于120°C温度下搅拌溶解,得到溶液一,即虾青素-β-环糊精包合物溶液;
步骤2:称取清凉剂,倒入剩余的纯化水,加热至70℃溶解,冷却至室温后,加入稀土元素、增稠剂,得到溶液二;
步骤3:将步骤1与步骤2得到的溶液混合搅拌,一种治疗湿疹皮炎的外用制剂。
所述稀土元素是由La和Ce以重量比1-3:1组成的混合物。
所述清凉剂为薄荷醇、薄荷酮、薄荷油、薄荷脑、桉叶油、菊花精、清凉醇或冰片。
所述增稠剂为甲壳素、罗望子胶或羟丙基淀粉醚。
实施例9
一种治疗湿疹皮炎的外用制剂,所述外用制剂为凝胶剂,凝胶剂包括如下重量百分比的原料:稀土元素2%、增稠剂8%、甘草酸0.5%、虾青素0.6%、β-环糊精3%、清凉剂0.8%,纯化水余量。
一种治疗湿疹皮炎的外用制剂的制备方法,其特征在于:包括如下步骤:
步骤1:称取虾青素、β-环糊精,加入占纯化水总重量50%的的纯化水,以30000Hz的超声频率进行超声分散,于130°C温度下搅拌溶解,得到溶液一,即虾青素-β-环糊精包合物溶液;
步骤2:称取清凉剂,倒入剩余的纯化水,加热至65℃溶解,冷却至室温后,加入稀土元素、增稠剂,得到溶液二;
步骤3:将步骤1与步骤2得到的溶液混合搅拌,一种治疗湿疹皮炎的外用制剂。
所述稀土元素是由Nd和Sm以重量比1:1组成的混合物。
所述清凉剂是由菊花精、薄荷脑和清凉醇以重量比3:1.5:1组成的混合物。
所述增稠剂是由羧甲基纤维素钠、卡波姆和甲壳素以重量比2:1:1组成的混合物
实施例10
一种治疗湿疹皮炎的外用制剂,所述外用制剂为凝胶剂,凝胶剂包括如下重量百分比的原料:稀土元素0.9%、增稠剂3%、甘草酸2%、虾青素0.05%、β-环糊精1.5%、清凉剂0.04%,纯化水余量。
一种治疗湿疹皮炎的外用制剂的制备方法,其特征在于:包括如下步骤:
步骤1:称取虾青素、β-环糊精,加入占纯化水总重量70%的的纯化水,以20000Hz的超声频率进行超声分散,于150°C温度下搅拌溶解,得到溶液一,即虾青素-β-环糊精包合物溶液;
步骤2:称取清凉剂,倒入剩余的纯化水,加热至80℃溶解,冷却至室温后,加入稀土元素、增稠剂,得到溶液二;
步骤3:将步骤1与步骤2得到的溶液混合搅拌,一种治疗湿疹皮炎的外用制剂。
所述稀土元素是由Pr、Pm和Eu以重量比1:1.8:1组成的混合物。
所述清凉剂是由薄荷醇、乳酸薄荷酯、2-异丙基-5-甲基-N-(2-(吡啶-4-基)乙基)环己烷甲酰胺以重量比1.5:1:1组成的混合物。
所述增稠剂是由羟乙基纤维素、海藻酸丙二醇酯和羟丙基淀粉醚以重量比0.6:1:1组成的混合物。
实施例11
本实施例与上述实施例1的不同之处在于:
所述喷雾剂还包括硼酸0.5%、中药提取物1%,所述中药提取物包括如下重量份的原料:槐胶5份、菝葜1份、乌梢蛇4份、黄芩1份、黄连1.5份、黄柏2份、五倍子1.5份、蛇床子4份、蒲公英2份、瑞连草2份、五除叶4份、忍冬藤8份、紫荆皮6份、大血藤5份、徐长卿3份、博落回2份、金银花1份、苦参3份,皂刺1份、赤芍8份,艾叶4份、苍耳1份、甘草3份和紫草1份。
实施例12
本实施例与上述实施例2的不同之处在于:
所述喷雾剂还包括纳米银0.01%,中药提取物2%,所述中药提取物包括如下重量份的原料:土茯苓12份、大黄8份、槐胶8份、菝葜1.5份、乌梢蛇5份、黄芩1.5份、黄连2份、黄柏3份、皂刺1.5份、赤芍9份,艾叶5份、苍耳1.5份、甘草4份和紫草2份。
实施例13
本实施例与上述实施例3的不同之处在于:
所述喷雾剂还包括纳米银0.01%、硼酸0.5%、中药提取物3%,所述中药提取物包括如下重量份的原料:土茯苓15份、黄连2.5份、黄柏4份、五倍子2.5份、蛇床子6份、地肤子6份、地锦草4份、马齿苋2份、蒲公英3份、瑞连草4份、五除叶6份、忍冬藤10份、紫荆皮8份、大血藤10份、徐长卿5份、博落回3份、金银花2份、苦参4份,皂刺2份、赤芍10份,艾叶6份、苍耳2份、甘草5份和紫草3份。
实施例14
本实施例与上述实施例4的不同之处在于:所述喷雾剂还包括纳米银0.01%、海藻糖0.002%、石墨烯0.001%。
试验结果表明实施例11到实施例14效果较好,特别是实施例13和14效果明显,但成本偏高,可以根据实际情况进行生产。
本发明制得的喷雾剂和凝胶剂临床使用一周后,显愈率可以达到85.4%(总病例48例,痊愈26例,显效15例,有效4例,无效3例),与对照组外涂皮炎平霜适当治疗显愈率58.3%(总病例48例,痊愈17例,显效11例,有效5例,无效15例)相比,总有效率高出27.1%,疗效显著,且治疗后无明显不良反应。显愈率=(痊愈例数+显效例数)/治疗总例数×100%,具体治疗标准和方法参见专利ZL201310473278.6。
以下是本发明试用时的几个典型病例,用量大小依创面而定:
1、黄某:年龄6个月,女性
尿布湿疹,用喷雾剂一个星期后症状全部消失。
2、赵某:年龄38岁,男性
过敏性皮炎,用凝胶剂一个星期后症状全部消失。
3、张某:年龄25岁,女性
接触性皮炎,用喷雾剂一个星期后症状明显减轻,二周后完全消失。
4、刘某:年龄42岁,男性
银屑病,用凝胶剂一个星期后皮损大部分消退,症状明显减轻。
综上,本发明的外用制剂兼有抗过敏、抗瘙痒、抗红肿等多种防治作用,止痒效果明显,可用于湿疹、过敏性皮炎、接触性皮炎、银屑病等皮炎的消炎、止痒、杀菌等治疗作用。
上述实施例为本发明较佳的实现方案,除此之外,本发明还可以其它方式实现,在不脱离本发明构思的前提下任何显而易见的替换均在本发明的保护范围之内。
Claims (9)
1.一种治疗湿疹皮炎的外用制剂,其特征在于:它采用稀土元素、甘草酸、虾青素、β-环糊精、清凉剂为主要成分。
2.根据权利要求1所述的一种治疗湿疹皮炎的外用制剂,其特征在于:该外用制剂由如下重量百分比的原料组成:稀土元素0.01%-5%,甘草酸0.1%-5%,虾青素0.001-1.0%,β-环糊精0.05%-5%,清凉剂0.001%-1.0%,增稠剂0.1%-10%,余量为纯化水。
3.根据权利要求1或2所述的一种治疗湿疹皮炎的外用制剂,其特征在于:所述稀土元素为La、Ce、Pr、Nd、Pm、Sm、Eu、Gd、Tb、Dy、Ho、Er、Tm、Yb、Lu、Y和Sc中的至少一种。
4.根据权利要求3所述的一种治疗湿疹皮炎的外用制剂,其特征在于:所述稀土元素为La、Ce、Pr、Nd、Pm、Sm和Eu中的至少一种。
5.根据权利要求1或2所述的一种治疗湿疹皮炎的外用制剂,其特征在于:所述清凉剂为薄荷酯、薄荷酰胺、薄荷醇、薄荷酮、薄荷油、薄荷脑、桉叶油、菊花精、清凉醇和冰片中的至少一种。
6.根据权利要求5所述的一种治疗湿疹皮炎的外用制剂,其特征在于:所述薄荷酯为3-羟基丁酸薄荷酯、琥珀酸薄荷酯、乳酸薄荷酯、戊二酸薄荷酯和乙酸薄荷酯中的至少一种;所述薄荷酰胺为N-(乙氧羰基甲基)-对薄荷烷-3-甲酰胺、N-乙基-对薄荷基-3-甲酰胺、N-(4-氰基甲基苯基)对-薄荷酰胺、2-异丙基-5-甲基-N-(2-(吡啶-4-基)乙基)环己烷甲酰胺和2-异丙基-N,2,3-三甲基丁酰胺中的至少一种。
7.根据权利要求2所述的一种治疗湿疹皮炎的外用制剂,其特征在于:所述增稠剂为甲基纤维素、羟乙基纤维素、羟丙基甲基纤维素、羧甲基纤维素钠、海藻酸丙二醇酯、卡波姆、淀粉磷酸酯钠、甲壳素、罗望子胶和羟丙基淀粉醚中的至少一种。
8.一种如权利要求2所述的治疗湿疹皮炎的外用制剂的制备方法,其特征在于:包括如下步骤:
步骤1:称取虾青素、β-环糊精,加入占纯化水总重量30%-70%的纯化水,以20000Hz-40000Hz的超声频率进行超声分散,于45-150°C温度下搅拌溶解,得到溶液一,即虾青素-β-环糊精包合物溶液;
步骤2:称取清凉剂,倒入剩余的纯化水,加热至60-80℃溶解,冷却至室温后,加入稀土元素,得到溶液二;
步骤3:将步骤1与步骤2得到的溶液混合搅拌,即得一种治疗湿疹皮炎的外用制剂。
9.根据权利要求8所述的一种治疗湿疹皮炎的外用制剂的制备方法,其特征在于:当该外用制剂制成凝胶时,步骤二中加入增稠剂。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811408500.3A CN109464621A (zh) | 2018-11-23 | 2018-11-23 | 一种治疗湿疹皮炎的外用制剂及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811408500.3A CN109464621A (zh) | 2018-11-23 | 2018-11-23 | 一种治疗湿疹皮炎的外用制剂及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN109464621A true CN109464621A (zh) | 2019-03-15 |
Family
ID=65674543
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811408500.3A Pending CN109464621A (zh) | 2018-11-23 | 2018-11-23 | 一种治疗湿疹皮炎的外用制剂及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109464621A (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110269809A (zh) * | 2019-06-27 | 2019-09-24 | 深圳百奥捷生物科技有限公司 | 一种采用低氘水配制的护肤营养液及其制备方法 |
CN110478514A (zh) * | 2019-06-18 | 2019-11-22 | 广西信业生物技术有限公司 | 一种抗hpv病毒敷料及其制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1140600A (zh) * | 1995-12-27 | 1997-01-22 | 张宏江 | 一种含稀土治疗皮肤癣菌病药剂的制配方法 |
JP2003335677A (ja) * | 2002-05-16 | 2003-11-25 | Toyama Prefecture | 抗掻痒剤 |
CN106234439A (zh) * | 2016-08-09 | 2016-12-21 | 北京赛特瑞科技发展有限公司 | 一种超级细菌抗菌消毒剂及其制备方法和用途 |
-
2018
- 2018-11-23 CN CN201811408500.3A patent/CN109464621A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1140600A (zh) * | 1995-12-27 | 1997-01-22 | 张宏江 | 一种含稀土治疗皮肤癣菌病药剂的制配方法 |
JP2003335677A (ja) * | 2002-05-16 | 2003-11-25 | Toyama Prefecture | 抗掻痒剤 |
CN106234439A (zh) * | 2016-08-09 | 2016-12-21 | 北京赛特瑞科技发展有限公司 | 一种超级细菌抗菌消毒剂及其制备方法和用途 |
Non-Patent Citations (2)
Title |
---|
20130410: "湿疹及皮炎", 《中国医学文摘•皮肤科学》 * |
郝飞等: "正确认识皮炎湿疹", 《实用皮肤病学杂志》 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110478514A (zh) * | 2019-06-18 | 2019-11-22 | 广西信业生物技术有限公司 | 一种抗hpv病毒敷料及其制备方法 |
CN110269809A (zh) * | 2019-06-27 | 2019-09-24 | 深圳百奥捷生物科技有限公司 | 一种采用低氘水配制的护肤营养液及其制备方法 |
CN110269809B (zh) * | 2019-06-27 | 2022-07-12 | 深圳百奥捷生物科技有限公司 | 一种采用低氘水配制的护肤营养液及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20190008907A1 (en) | Compositions for management of wounds, skin diseases, dehydration, chronic diseases, and respiratory diseases | |
CN111202822A (zh) | 一种妇科外用抗菌喷剂及其制备方法 | |
EP2775838B1 (en) | Aqueous antimicrobial composition containing coniferous resin acids | |
CN107468561A (zh) | 一种天然多功能膏霜及其制备 | |
CN103041111B (zh) | 一种妇科会阴护理液及其制备方法 | |
CN101444555B (zh) | 一种治疗口腔溃疡的纯中药膜及其制备方法 | |
CN108403909A (zh) | 一种外用抑菌剂、其制备方法及其应用 | |
US9662356B1 (en) | Propolis-metal nanoparticle composition and methods of use | |
CN109464621A (zh) | 一种治疗湿疹皮炎的外用制剂及其制备方法 | |
Samarh et al. | Evidence based medical use of aloe vera extracts, short review of literature | |
CN113244382B (zh) | 一种止痒消肿组合物及其制备方法和应用 | |
CN110917213A (zh) | 纳米碳粉外用治疗皮肤炎症的药物及其制备和应用 | |
CN109091584A (zh) | 一种消肿止痛药膏及其制备方法 | |
Semkina | Ointments, gels, liniments, and creams containing phytopreparations (a review) | |
CN103202881A (zh) | 一种治疗皮疹的外用剂组合物 | |
CN106913602A (zh) | 一种艾纳香妇科洗液及其制备方法和应用 | |
CN111773341A (zh) | 一种治疗仔猪疥癣病的复方中草药外用制剂 | |
CN113274428A (zh) | 一种治疗急性瘙痒性皮肤病软膏及其制备方法 | |
US12350335B2 (en) | Homeopathic topical composition | |
CN111358851A (zh) | 一种用于治疗宠物皮肤病的凝胶剂及其制备方法 | |
CN100551420C (zh) | 一种具有抗生素功效的中药外用乳浊液制剂及其制备方法 | |
CN103751073B (zh) | 一种具有祛屑功能的复方中药提取物及应用 | |
CN109045029A (zh) | 一种咪唑并吡啶衍生物的用途 | |
CN108186705A (zh) | 一种抗炎的凝胶剂及其制备方法 | |
CN100356910C (zh) | 一种治疗脚气的药物组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190315 |